MALVERN, Pa., Dec. 10, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that it has begun shipping doxycycline for injection, USP 100 mg/vial, an AP-rated version of DOXY 100™.
"We're pleased to provide choices to healthcare providers and hospital pharmacies as they work to deliver quality patient care," said Scott Sims, Senior Vice President and General Manager, Injectable Solutions & Generics at Endo. "The doxycycline for injection strengthens our sterile injectable product portfolio and underscores our reputation as a reliable supplier of aseptic medicines."
According to IQVIA®, doxycycline for injection 100 mg vial sales were approximately $49 million for the 12 months ended September 30, 2024.
DOXY 100™ is a trademark of Fresenius Kabi. Read more >
Through our long-standing work in endocrinology, orthopedics, and urology, as well as in hospital systems and with retail generic medications, we have developed an unmatched understanding of those we serve. We will never stop learning how to make a real difference in people's lives. We partner with hospitals and healthcare systems to reduce complexity through life-enhancing solutions, innovating together to add value where it matters—from manufacturing to treatment—so that healthcare providers can focus on patient care. We deliver high-quality, affordable generic medicines to patients in need through excellence in development, manufacturing, and commercialization. Drawing from over four decades of experience in the U.S. generic pharmaceutical market, we have built a well-established reputation for compliance and exceptional customer service.
